Bringing Value Assessments into the 21st Century: A Multi-Stakeholder Perspective

With growing inflation and economic turmoil, budgets are tighter than ever. Governments and other payers are looking to cut overall spending and one of their targets is again healthcare, specifically pharmaceuticals. To determine the value of medicines, and if/how spending can be reduced, governments and other payers are increasingly leaning on value assessments made by Health Technology Assessment Organizations (HTAs). But are these HTAs taking a holistic viewpoint or are they just focused on cost? How does a cost-first/only approach limit outcomes and impact patients and society? How can industry help providers and patients better understand the value of medicines? And how does this all relate to equitable access?

Hear from a leading pharmaceutical company, one of America’s largest group purchasing organizations, an organization focused on value assessments, and a patient advocate, as they discuss how best to recommend approaching value assessments to work better for patients or societies.